Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1644296

Feasibility and Safety of Hepatic Artery Infusion Chemotherapy via the Distal Transradial access for hepatocellular carcinoma

Provisionally accepted
Wu  YiWu YiChunlin  YuChunlin YuXinghai  LiXinghai LiBaoliang  ZhongBaoliang ZhongDaolin  ZengDaolin ZengYunfei  TianYunfei Tian*
  • Ganzhou People's Hospital, Ganzhou, China

The final, formatted version of the article will be published soon.

Background and Purpose: Hepatocellular carcinoma (HCC) remains a global health challenge, with hepatic artery infusion chemotherapy (HAIC) serving as a pivotal treatment for unresectable cases. Traditional transfemoral access (TFA) for HAIC is associated with significant limitations, including prolonged immobility, increased risk of deep vein thrombosis (DVT), and reduced quality of life. The distal transradial access (dTRA), emerging as a viable alternative in coronary and neurovascular interventions, offers potential advantages in HAIC. This study evaluates the feasibility, safety, and clinical outcomes of dTRA for HAIC in HCC patients, addressing the paucity of data in this specific application. Methods: A retrospective analysis was conducted on patients who underwent dTRA-HAIC procedures for HCC between November 2023 and December 2024. The puncture time, procedural time, incidence of distal radial artery occlusion (d-RAO) and access site complications (ASC) were used to evaluate the treatment efficacy in the patients. Univariate and multivariate logistic regression analysis was performed to identify predictive factors associated with d-RAO development. Results: The mean puncture time was 3.5 minutes (3–4.25 minutes), with a distal radial artery diameter of 1.96±0.16 mm. The mean catheter indwelling time for mFOLFOX-HAIC and Ralox-HAIC were 2375 minutes (1715-3276 minutes) and 410 minutes (276, 544 minutes), respectively. Early d-RAO rates were 25.4% on postoperative day 1, declining to 20.6% at 6 months. Multivariate analysis identified preoperative D-dimer levels (p < 0.05) as significant risk factors for early d-RAO in one-month after operation. Multiple punctures may be associated with a high risk of d-RAO. No severe bleeding, hematoma, or pseudoaneurysm occurred. Conclusion: dTRA for HAIC demonstrates high technical feasibility and acceptable safety, representing a promising alternative to TFA. Preoperative D-dimer screening and limitations on repeated punctures may optimize outcomes. Larger multicenter studies are warranted to validate these findings and refine patient selection criteria.

Keywords: Hepatocellular Carcinoma, Distal transradial access (dTRA), hepaticartery infusion chemotherapy, feasibility, Safety

Received: 10 Jun 2025; Accepted: 08 Oct 2025.

Copyright: © 2025 Yi, Yu, Li, Zhong, Zeng and Tian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Yunfei Tian, jieruwy01@126.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.